In particular, the deregulation of p53 and RB1 axis, a frequent event in osteosarcoma [1,57,58], might define the crossroad of intersecting pathways shaping the ultimate cellular fate during drug treatment [30,33,59]. This evidence concerns the gene TP53 and osteosarcoma.